Recombinant Human Granulocyte Macrophage Colony Stimulating Factor

  • Prevention and treatment of leucopenia caused by chemotherapy or radiotherapy of tumour
  • Treatment of bone marrow hematopoietic malflaction and myelodysplastic syndrome
  • Prevention of potential infection complication induced by leucopenia
  • Acceleration of recovery of neutropenia induced by infections
  • Te'erli™ (molgramostim, rHuGM-CSF) is a recombinant protein, and displays a broader range of haematopoietic activities.
  • Te'erli™ interacts with early, multipotent progenitor cells, promoting the proliferation and differentiation of burst and colony-forming units.
  • It not only reverses the neutropenia of myelodysplastic syndrome and aplastic anemia, but also enhances recovery from bone marrow transplantation and thus reduce the attendant morbidity of this procedure.
  • Te'erli™ rapidly recovers neutropenia during anti-cancer chemotherapy and shortens the period during which patients are supposed to the risk of infection and thereby enables us to complete planned anti-cancer chemotherapies.
Te'erli™ finished its clinical trial in March 1997. The results show that Te'erli™ is a cytokine with therapeutic effect and safety. It can shorten markedly the duration of leucopenia and neutropenia.
  • P.R.C. Government License No. (98) XIATEBAO S-01; S-02; S-03
  • China Certification of GMP for Human Drugs (No. B0272)
  • The first domestic marketing Molgramostim in China

Related link: